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The potential for organophosphate insecti-
cides, notably chlorpyrifos (CPF), to elicit
developmental neurotoxicity has led to increas-
ing concern and restricted use [Barone et al.
2000; Landrigan 2001; Landrigan et al. 1999;
May 2000; Physicians for Social Responsibility
1995; Pope 1999; Rice and Barone 2000;
Slotkin 1999, In press a; U.S. Environmental
Protection Agency (EPA) 2000a, 2000b]. The
systemic toxicity of organophosphates reﬂects
their ability to inhibit cholinesterase, but it is
now evident that other mechanisms are at least
equally, if not more, important in determining
the long-term liability of fetal or neonatal CPF
exposure (Barone et al. 2000; Das and Barone
1999; Pope 1999; Schuh et al. 2002; Slotkin
1999, In press a). The cyclic AMP (cAMP)
signaling pathway has received particular atten-
tion because this second messenger coordinates
the critical transition from cell replication to
cell differentiation in virtually all prokaryotic
and eukaryotic cells (Bhat et al. 1983;
Claycomb 1976; Guidotti 1972; Hultgårdh-
Nilsson et al. 1994; Van Wijk et al. 1973). A
number of studies in the developing brain have
centered on the effects of CPF on the receptors
and signaling proteins that control the activity
of adenylyl cyclase (AC), the enzyme that syn-
thesizes cAMP, as well as on the downstream
elements that are targets for cAMP (Crumpton
et al. 2000; Garcia et al. 2001; Meyer et al.
2003; Olivier et al. 2001; Schuh et al. 2002;
Song et al. 1997; Zhang et al. 2002).
Recent attention has begun to explore the
contributions of fetal factors and chemical
exposures to the later emergence of cardio-
vascular and metabolic diseases. The “Barker
Hypothesis” originally drew a connection
between fetal growth retardation and the sub-
sequent incidence of coronary artery disease
and diabetes (Barker 2003; Phillips 2002),
and there is also signiﬁcant literature on the
long-term consequences of prenatal stress and
the role of glucocorticoid hormones (Dodic
et al. 1999, 2001; Nyirenda and Seckl 1998).
More recently, there are suggestions that
environmental toxicants may play an impor-
tant contributory role in such disorders as
hypertension, diabetes, and obesity, beyond
neural contributions (Power and Jefferis
2002; Slikker and Schwetz 2003; Toschke
et al. 2002). Thus, although most studies on
the developmental effects of CPF are appro-
priately directed toward neurotoxicity, the
present work instead takes a similar approach
with regard to cell signaling in the liver and
heart, concentrating on the cAMP cascade
and its responses to some of the major inputs
that control that pathway, β-adrenoceptors
(βARs), and glucagon receptors (Figure 1).
CPF is concentrated in developing peripheral
tissues, especially the liver (Hunter et al.
1998), and high doses can be hepatotoxic
(Goel et al. 2000). Significant effects in the
immature liver or heart are elicited at expo-
sures below the threshold for systemic toxic-
ity, and these include effects on signal
transduction (Auman et al. 2000; Song et al.
1997) and cell number and size (Qiao et al.
2002). The present study addresses several
essential questions: What is the critical period
for effects of CPF on signal transduction in
the liver and heart? Are CPF-induced signal-
ing abnormalities present in adulthood? If so,
do the adult effects represent persistence of
alterations that were elicited during the initial
CPF exposure, or alternatively, does CPF dis-
rupt the programming of cell signaling so that
defects arise only after a delay?
Materials and Methods
Animal treatments. All experiments using live
animals were carried out in accordance with
the declaration of Helsinki and with the
Guide for the Care and Use of Laboratory
Animals (Institute of Laboratory Animal
Resources 1996) as adopted and promulgated
by the National Institutes of Health. Timed-
pregnant Sprague–Dawley rats were housed
in breeding cages, with a 12-hr light/dark
cycle and with free access to food and water.
CPF was dissolved in DMSO to provide
rapid and complete absorption (Whitney
et al. 1995) and was injected subcutaneously
in a volume of 1 mL/kg body weight; control
animals received vehicle (DMSO) injections
on the same schedules. For exposure on gesta-
tional days (GD) 9–12, dams were injected
daily with CPF at 1, 2, or 5 mg/kg body
weight, and for later gestational exposure
(GD17–20), dams were given CPF daily over
a range of 1–40 mg/kg; tissues were harvested
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inhibition of fetal brain cholinesterase activ-
ity, fetal growth impairment, or reduced
maternal weight gain, all of which become
evident at about 5 mg/kg (Garcia et al. 2003;
Qiao et al. 2002). Additional dams were
treated on GD9–12 or GD17–20 with 1 or
5 mg/kg for measurements in the offspring
when they reached adulthood [postnatal day
(PN) 60]. On the day of birth, all pups were
randomized within their respective treatment
groups and redistributed to the dams with a
litter size of 10 to maintain a standard nutri-
tional status. Randomization was repeated at
intervals of several days; in addition, dams
were rotated among litters to distribute any
maternal caretaking differences randomly
across litters and treatment groups. Offspring
were weaned on PN21.
For studies of CPF effects in the ﬁrst few
days after birth, animals were subcutaneously
injected with 1 mg/kg daily on PN1–4; for
studies in older animals, which tolerate higher
doses (Campbell et al. 1997; Pope and
Chakraborti 1992; Pope et al. 1991; Whitney
et al. 1995), animals were treated daily with 5
mg/kg on PN11–14. The same randomiza-
tion procedure was followed. Neither regimen
evokes weight loss or mortality (Campbell
et al. 1997; Dam et al. 1998; Johnson et al.
1998; Song et al. 1997), and in the present
study we did not observe any changes in suck-
ling or maternal caretaking. Animals were
selected 24 hr and 6 days after the last CPF
injection, and at PN60.
These prenatal and postnatal CPF regi-
mens have been previously shown to alter brain
development without eliciting overt systemic
toxicity (Slotkin 1999, In press a, In press b).
Behavioral differences remain apparent, or may
ﬁrst emerge, after weaning (Dam et al. 2000;
Levin et al. 2001, 2002).
For each experiment, animals were decap-
itated and the tissues were frozen with liquid
nitrogen and stored at –45°C. Preliminary
experiments showed no changes in any of the
measures as a result of freezing and storage.
Membrane preparation. Tissues were
thawed and homogenized (Polytron;
Brinkmann Instruments, Westbury, NY) in
39 volumes of ice-cold buffer containing
145 mM sodium chloride, 2 mM magnesium
chloride, and 20 mM Tris (pH 7.5), strained
through several layers of cheesecloth to remove
connective tissue, and the homogenates were
sedimented at 40,000 × g for 15 min. The pel-
lets were washed twice by resuspension
(Polytron) in homogenization buffer followed
by resedimentation and were then dispersed
with a homogenizer (smooth glass ﬁtted with
Teﬂon pestle) in a buffer consisting of 250 mM
sucrose, 2 mM MgCl2, and 50 mM Tris.
Assays. To evaluate βAR binding, aliquots
of membrane preparation were incubated
with [125I]iodopindolol (final concentration,
67 pM) in 145 mM NaCl, 2 mM MgCl2,
1 mM sodium ascorbate, 20 mM Tris (pH
7.5), for 20 min at room temperature in a
total volume of 250 µL. Incubations were
stopped by dilution with 3 mL ice-cold
buffer, and the labeled membranes were
trapped by rapid vacuum ﬁltration onto glass
fiber filters, which were then washed with
additional buffer and counted by liquid scin-
tillation spectrometry. Nonspecific binding
was assessed by displacement with 100 µM
isoproterenol.
For assessment of AC activity, aliquots of
the same membrane preparation were incu-
bated for 30 min at 30°C with ﬁnal concen-
trations of 100 mM Tris-HCl (pH 7.4),
10 mM theophylline, 1 mM ATP, 2 mM
MgCl2, 1 mg/mL bovine serum albumin, and
a creatine phosphokinase–ATP–regenerating
system consisting of 10 mM sodium phospho-
creatine and 8 IU/mL phosphocreatine kinase,
with 10 µM GTP in a total volume of 250 µL.
The enzymatic reaction was stopped by plac-
ing the samples in a 90–100°C water bath for
5 min, followed by sedimentation at 3,000 × g
for 15 min, and the supernatant solution was
assayed for cAMP using radioimmunoassay.
Preliminary experiments showed that the
enzymatic reaction was linear well beyond the
assay period and was linear with membrane
protein concentration; concentrations of
cofactors were optimal, and, in particular,
higher concentrations of GTP produced no
further augmentation of activity.
AC activity was evaluated in several ways
(Figure 1). First, we measured basal AC activity
without addition of any stimulants. Next, we
compared the responses to activation of two
stimulatory G-protein (Gs)-coupled receptors,
the βAR, and glucagon receptor, using 100 µM
isoproterenol or 3 µM glucagon, respectively.
Third, we evaluated the effects of global activa-
tion of all G-proteins elicited by sodium ﬂuo-
ride (10 mM). Finally, we compared the
responses of two direct AC stimulants, forskolin
(100 µM) and Mn2+ (10 mM); these discrimi-
nate the effects of Gs–AC association, which
selectively enhances the forskolin response
(Limbird and Macmillan 1981), as well as
allowing for detection of shifts in the AC iso-
form (Zeiders et al. 1999b). The concentrations
of each stimulant produce maximal responses,
as assessed in earlier studies (Auman et al. 2000,
2001; Zeiders et al. 1997, 1999a).
Data analysis. For treatments given to
dams, only one fetus was used from each dam,
so the number of determinations represents
the number of dams. The fetuses were derived
from the same litters as those used in two ear-
lier studies on cell damage and cholinergic
biomarkers (Garcia et al. 2002; Qiao et al.
2002), and effects on cholinesterase activity,
maternal and fetal body weights, and other lit-
ter characteristics appear in those publications.
For postnatal determinations, each litter con-
tributed no more than one male and one
female for a given set of determinations.
Data are presented as means and SEs. For
convenience, some results are given as the per-
cent change from control values, but statistical
evaluations were always conducted on the origi-
nal data. To establish treatment differences in
receptor binding or AC activity, a global analy-
sis of variance (ANOVA; data log transformed
whenever variance was heterogeneous) was ﬁrst
conducted across the in vivo treatment groups,
ages, sexes, tissues, and the measurements made
on the membranes (βAR binding, AC activity
under six different conditions); the latter were
considered to be repeated measures because
each membrane preparation was used for the
multiple conditions under which AC was deter-
mined. As justiﬁed by signiﬁcant interactions of
treatment with the other variables, data were
then subdivided to permit testing of individual
treatments and AC measures that differed from
control values; these were conducted by lower-
order ANOVAs, followed, where appropriate,
by Fisher’s protected least signiﬁcant difference
test to identify individual values for which the
CPF groups differed from the corresponding
control. For all tests, signiﬁcance for main treat-
ment effects was assumed at p < 0.05; however,
for interactions at p < 0.1, we also examined
whether lower-order main effects were
detectable after subdivision of the interactive
variables (Snedecor and Cochran 1967).
For presentation, control values were
combined across the multiple cohorts (con-
trols used for administration on GD9–12,
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Figure 1. Mechanisms controlling AC activity in
developing rat cardiac and hepatic cells. Both βARs
and glucagon receptors enhance AC activity
through the stimulatory G-protein, Gs. Each step in
the pathway can be probed with the appropriate
stimulant: isoproterenol for βARs, glucagon for the
glucagon receptor, NaF for the G-proteins, and
forskolin and Mn2+ for AC itself. The attachment of
Gs to AC (+) enhances the response to forskolin
while suppressing the response to Mn2+; in addition,
different AC isoforms show preferential responses
to forskolin versus Mn2+. When alterations involve
signaling elements downstream from the receptors
(Gs, AC), effects will be shared by multiple receptors
and will therefore be “heterologous.”
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NaF
ATP cAMP
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receptorGD17–20, PN1–4, PN11–14). However,
statistical comparisons of the effects of CPF
were made only with the appropriately
matched control cohort.
Materials. Animals were purchased from
Zivic Laboratories (Pittsburgh, PA, USA).
CPF was obtained from Chem Service (West
Chester, PA, USA). [125I]Iodopindolol (spe-
cific activity, 2,200 Ci/mmol) was from
Perkin-Elmer Life Sciences (Boston, MA,
USA), and cAMP radioimmunoassay kits
were purchased from Amersham Biosciences
(Piscataway, NJ, USA). All other chemicals
were bought from Sigma Chemical Company
(St. Louis, MO, USA).
Results
Development of βAR binding and AC in
controls. In accordance with earlier results
(Auman et al. 2000; McMillian et al. 1983;
Navarro et al. 1991), large ontogenetic
changes were observed in the development of
βAR binding and AC responses to different
stimulants in heart and liver over the course
from late gestation to adulthood (Table 1).
Cardiac βARs decreased about 50% over that
period, whereas the liver showed a much
more profound decrease that was paralleled
by a loss of basal AC activity. The tissues also
displayed large disparities in AC activities
measured in the presence of specific stimu-
lants. In the heart, activity with addition of
isoproterenol, glucagon, NaF, and forskolin
all increased with age, but for Mn2+, the effect
was diminished in adulthood. In the liver,
only the forskolin-stimulated activity was
higher in adulthood than in the fetus, and all
other measures showed a decrease in AC.
There were only minor sex differences in
adulthood, with females showing slightly
higher hepatic βAR binding and slightly
higher isoproterenol-stimulated cardiac AC.
Because the stimulant-associated AC activi-
ties were superimposed on large ontogenetic
changes in basal AC, the values were reassessed
as the speciﬁc response, the ratio of AC with
stimulant to basal AC. Despite the ontogenetic
decline in βAR binding, the cardiac AC
response to isoproterenol doubled between
GD21 and adulthood, paralleled by a similar
rise in the response to glucagon (Figure 2A). In
contrast, the hepatic AC response to isopro-
terenol declined significantly in adulthood,
whereas the response to glucagon was markedly
higher than in the fetus. Disparities between
the two tissues were similarly displayed by the
response to direct AC stimulants (Figure 2B).
In the heart on GD21, the response to
forskolin was nearly double that to Mn2+, and
the forskolin response increased with age,
whereas that to Mn2+ did not. Accordingly, the
forskolin:Mn2+ preference ratio doubled over
the course of development. In the liver, the ini-
tial response to Mn2+ was greater than that to
forskolin; although both stimulants showed an
increased response in adulthood, the preferen-
tial effect for Mn2+ was lost, such that nearly
equivalent responses were seen for the two
stimulants. Accordingly, both tissues showed
ontogenetic changes in the forskolin:Mn2+
preference ratio suggestive of an isoform shift
(Zeiders et al. 1999b).
Systemic toxicity of CPF. In keeping with
earlier reports (Garcia et al. 2002; Qiao et al.
2002), CPF treatment on GD9–12 impaired
maternal weight with a threshold at 5 mg/kg,
displaying small, transient deﬁcits that resolved
completely by parturition (data not shown).
Similarly, as found before (Garcia et al. 2002;
Qiao et al. 2002), the GD17–20 CPF regimen
had a similar threshold, with progressively
larger deﬁcits as the dose was raised to 10, 20,
or 40 mg/kg (data not shown). With either
regimen, GD21 fetal heart weights remained
normal at all CPF doses, but liver weights were
reduced in animals receiving doses above
5 mg/kg; the effects on tissue weights have
already been reported (Garcia et al. 2002; Qiao
et al. 2002). Neither regimen affected the
number of fetuses or fetal viability, nor were
there effects on the number of pups at term or
on neonatal viability. As found earlier, the
postnatal treatment regimens had no signifi-
cant effects on body, heart, or liver weights
24 hr or 6 days after the end of CPF treatment
(Auman et al. 2000; Song et al. 1997).
In adulthood, animals receiving prenatal
or postnatal CPF regimens did not display any
consistent differences in body weights (data
not shown), in agreement with earlier reports
(Dam et al. 1999; Qiao et al. 2003); the group
exposed to CPF on GD9–12 showed a small
(< 10%) reduction in body weight at 1 mg/kg
(p < 0.006) but not at 5 mg/kg. Heart weights
were similarly unaffected by all treatments
except the GD9–12 regimen, which displayed
the same inconsistent effect, a 7% reduction at
1 mg/kg (p < 0.006) without any significant
difference at 5 mg/kg. Comparisons of liver
weights were not done because only one lobe
was sampled on PN60.
CPF exposure on GD9–12. In the heart,
animals treated with CPF on GD9–12 showed
immediate (GD21) and long-term (PN60)
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Table 1. Development of βAR binding and AC activities in controls.
GD21 PN60
(n = 16) Male (n = 28) Female (n = 28)
Heart
βAR binding (fmol/mg protein) 19.4 ± 0.8 10.4 ± 0.3* 10.4 ± 0.2*
Basal AC 12.2 ± 0.4 9.1 ± 0.3* 9.6 ± 0.3*
Isoproterenol-stimulated AC 16.2 ± 0.5 25 ± 1* 29 ± 1*,**
Glucagon-stimulated AC 12.6 ± 0.4 23.8 ± 0.9* 26 ± 1*
NaF-stimulated AC 42 ± 2 64 ± 2* 69 ± 3*
Forskolin-stimulated AC 235 ± 12 304 ± 13* 300 ± 9*
Mn2+-stimulated AC 135 ± 7 100 ± 5* 103 ± 4*
Liver
βAR binding (fmol/mg protein) 27.7 ± 0.7 4.9 ± 0.1* 6.5 ± 0.2*,**
Basal AC 15.1 ± 0.4 3.52 ± 0.07* 3.35 ± 0.06*
Isoproterenol-stimulated AC 27 ± 1 4.7 ± 0.1* 4.91 ± 0.09*
Glucagon-stimulated AC 30 ± 2 27.1 ± 0.4* 26.2 ± 0.5*
NaF-stimulated AC 46 ± 1 28.0 ± 0.6* 27.5 ± 0.5*
Forskolin-stimulated AC 41 ± 3 49 ± 2* 45 ± 1*
Mn2+-stimulated AC 63 ± 2 50 ± 1* 49 ± 1*
Values shown are in picomoles per minute per milligram of protein except where noted. Values were combined across
multiple cohorts (controls used for CPF administration on GD9–12, GD17–20, PN1–4, and PN11–14); however, statistical
comparisons of the effects of CPF were made only with the appropriately matched control cohort. 
*Signiﬁcantly different from GD21. **Signiﬁcantly different from male.
Figure 2. Development of responses to AC stimu-
lants in control animals. (A) Responses to receptor-
mediated stimulation by isoproterenol (Iso) or
glucagon. (B) Responses to direct AC stimulants
forskolin and Mn2+. Data represent means and SEs
of the ratios of each stimulant to basal AC activity,
obtained from 16–28 animals in each group. With
the exception of cardiac Mn2+ responses, ANOVA
indicates a signiﬁcant change with age (p < 0.0001). 
*The only response for which a sex difference was seen
on PN60.
8
6
4
2
0
Iso:basal Glucagon:basal Glucagon:basal Iso:basal
Forskolin:basal Forskolin:basal Mn2+:basal Mn2+:basal
40
35
30
25
20
15
10
5
0
R
a
t
i
o
R
a
t
i
o
Heart Liver
Heart Liver
GD21
PN60 male
PN60 female
A
B
*alterations in βAR binding and AC responses.
On GD21, there was signiﬁcant up-regulation
of cardiac βARs at the two lowest CPF doses,
but the effect disappeared when the dose was
raised to 5 mg/kg, above the threshold for sys-
temic toxicity (Figure 3A). Consistent with this
pattern, AC activities also showed augmenta-
tion at subtoxic CPF exposures and loss of the
effect at 5 mg/kg. This hormetic effect was sta-
tistically significant across all AC measures
(p < 0.02 for CPF 5 mg/kg vs. 1 mg/kg;
p < 0.01 for CPF 5 mg/kg vs. CPF 2 mg/kg).
For AC activities, the most profound effect
was on the response to Mn2+, which showed
elevations as high as 60% above control val-
ues, effects that far exceeded the smaller
induction of the other AC measures. In partic-
ular, there was a statistically significant (p <
0.005) preferential effect on the Mn2+
response compared with the forskolin
response, suggestive of an AC isoform shift. A
smaller but signiﬁcant (p < 0.03) shift was seen
in the ratio of NaF to basal activity, indicative
of a defect in G-protein signal transduction:
control, 3.27 ± 0.21; CPF 1 mg/kg, 2.70 ±
0.09 (p < 0.005); CPF 2 mg/kg, 2.76 ± 0.05 (p
< 0.02); CPF 5 mg/kg, 2.93 ± 0.11.
In contrast to the effects seen in the heart,
the immediate (GD21) alterations in hepatic
βARs and AC were much less notable, and
neither set of variables achieved overall statis-
tical signiﬁcance (Figure 3B). The lack of sig-
nificant effect in the liver was statistically
distinguishable from the changes seen in the
heart, as evidenced by interactions of treat-
ment × tissue (p < 0.0001) and treatment ×
tissue × measure (p < 0.0001).
At adulthood (PN60), animals exposed to
CPF on GD9–12 showed major alterations in
βARs and AC signaling proﬁles. In the heart
(Figure 4A), animals that received the low dose
of CPF (1 mg/kg) displayed overall increases in
AC measures that were sex selective, with sig-
niﬁcant elevations in males but not in females.
There were no differential effects detected
among the various AC measures, implying that
activity was enhanced globally (i.e., induction
of total AC activity), rather than involving spe-
ciﬁc changes in receptor-mediated responses,
G-protein coupling, or AC isoform shifts. To
evaluate whether these effects were secondary
to systemic toxicity of CPF, we also evaluated
a higher dose (5 mg/kg) that was at the thresh-
old for impairment of maternal weight gain
during the treatment period; presumably,
effects due to toxicity would show an enhance-
ment at the higher dose. Instead, however, we
found the same pattern but with smaller
effects: AC elevations in males were no longer
statistically significant, and values in females
tended to be subnormal.
Across both the heart and liver on PN60,
the main effect of CPF was statistically signiﬁ-
cant (p < 0.04), but when hepatic values were
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Figure 4. Effects of GD9–12 CPF exposure on (A)
cardiac and (B) hepatic βAR binding and AC activity
on PN60. Abbreviations: Fsk, forskolin; Glu,
glucagon; Iso, isoproterenol; NS, not signiﬁcant; Rx,
treatment. Data represent means and SEs obtained
from eight animals in each treatment group for
each sex, shown as the percent change from corre-
sponding control values (Table 1). Across both tis-
sues, ANOVA indicates significant sex-dependent
effects on βAR binding (p < 0.04 for treatment ×
sex). For AC activities, the overall ANOVA showed
treatment effects that differed between the two tis-
sues and among the different AC measures (p < 0.04
for treatment × tissue × measure), necessitating
separate comparisons for heart and liver. ANOVAs
across both CPF doses are as follows: for (A), Rx ×
measure, p < 0.1; Rx × sex × measure, p < 0.02; for
(B), NS (p < 0.09). ANOVAs for each dose are shown
within the ﬁgure. Signiﬁcance testing for individual
AC values was not done because of the absence of
treatment × measure interactions after subdivision
of the data into the separate tissues and doses.
*Individual group differs signiﬁcantly from control.
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Figure 5. Effects of GD17–20 CPF exposure on (A)
cardiac and (B) hepatic βAR binding and AC activ-
ity on GD21. Abbreviations: Fsk, forskolin; Glu,
glucagon; Iso, isoproterenol;  Rx, treatment. Data
represent means and SEs obtained from six ani-
mals in each treatment group, shown as the per-
cent change from corresponding control values
(Table 1). Across both tissues, ANOVA indicates
signiﬁcant treatment effects that differed between
the two tissues, justifying separate comparisons
for heart and liver: βAR binding, p < 0.0001 for
treatment × tissue; AC activities, p < 0.004 for treat-
ment × tissue, p < 0.02 for treatment × tissue ×
measure. Lower-order ANOVAs for each tissue are
shown within the ﬁgure.
*Individual groups differ significantly (calculated only for
variables showing a signiﬁcant overall effect by ANOVA).
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Figure 3. Effects of GD9–12 CPF exposure on (A)
cardiac and (B) hepatic βAR binding and AC activity
on GD21. Abbreviations: Fsk, forskolin; Glu,
glucagon; Iso, isoproterenol; NS, not signiﬁcant; Rx,
treatment. Data represent means and SEs obtained
from six animals in each treatment group, shown as
the percent change from corresponding control val-
ues (Table 1). Across both tissues, ANOVA indi-
cates significant treatment effects that differed
between the two tissues, justifying separate com-
parisons for heart and liver: βAR binding, p < 0.004
for treatment × tissue; AC activities, p < 0.0001 for
treatment × tissue, p < 0.0001 for treatment × tissue
× measure. Lower-order ANOVAs for each tissue
are shown within the ﬁgure. 
*Individual groups differ signiﬁcantly from the control (cal-
culated only for variables showing a significant overall
effect by ANOVA).
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5 mg/kgexamined separately, the tendency toward
elevated AC activities was only at the margin of
signiﬁcance (Figure 4B). Hepatic βAR binding
was signiﬁcantly elevated only in males.
CPF exposure on GD17–20. Animals
treated with CPF during late gestation
(GD17–20) presented a different pattern of
immediate and delayed-onset alterations in
βAR binding and AC activity from those
receiving treatment earlier in gestation. For the
immediate effects on GD21, the response pat-
terns for animals receiving CPF on GD17–20
were statistically distinguishable from those
treated on GD9–12 (p < 0.05 for treatment ×
regimen). In the heart (Figure 5A), GD17–20
exposure at CPF doses below (1 or 2 mg/kg)
and up to the threshold (5 mg/kg) for sys-
temic toxicity failed to cause signiﬁcant alter-
ations in βAR binding or any of the AC
measures on GD21. Raising the dose further
elicited signiﬁcant decrements in cardiac βAR
binding but still failed to cause any consistent
changes in AC. In the liver, CPF exposures of
1, 2, or 5 mg/kg similarly did not alter any of
the parameters, but higher doses suppressed
virtually all AC measures in a parallel manner
(Figure 5B).
For examination of effects in adulthood
(PN60), we again chose two dose groups, one
(1 mg/kg) well below the threshold for fetal
cholinesterase inhibition or impaired mater-
nal weight gain (Qiao et al. 2002) and one
(5 mg/kg) at or above the threshold. Animals
exposed to 1 mg/kg CPF on GD17–20 dis-
played sex-dependent effects on cardiac βARs
and AC activities in adulthood (Figure 6A).
Males showed elevated βAR binding,
although this effect did not correspond to an
elevation in the cardiac AC response to iso-
proterenol. Instead, most of the AC measures
found to be increased were in females, with
the notable exception of glucagon-stimulated
AC, which was unchanged. Because both
βARs and glucagon receptors operate through
Gs to stimulate AC, we compared the effect
on the isoproterenol response with that on
the glucagon response and found a signiﬁcant
reduction (p < 0.006) in the relative response
to glucagon (glucagon:isoproterenol response
ratio, 0.97 ± 0.04 in control females, 0.82 ±
0.03 in females exposed to CPF 1 mg/kg).
Again, raising the CPF exposure above the
threshold for systemic effects did not produce
significant enhancement of the long-term
effects on cardiac βARs or AC activity and
instead diminished the βAR effect in males;
in addition, the higher dose elicited signifi-
cant reductions in cardiac AC measures that
were not seen at the lower exposure.
In the liver on PN60 (Figure 6B), ani-
mals exposed to 1 mg/kg CPF on GD17–20
displayed signiﬁcant suppression of glucagon-
and forskolin-stimulated AC activity, with-
out demonstrable sex selectivity. Raising the
dose above the threshold for systemic toxicity
(5 mg/kg) did not intensify the effects but
rather reduced them.
CPF exposure on PN1–4. In an earlier
study (Song et al. 1997), we found that expo-
sure to 1 mg/kg CPF on PN1–4 evoked
short-term (PN5, PN10) deﬁcits in basal car-
diac AC activity without signiﬁcant effects on
the response to AC stimulants; there were no
effects on βAR binding. Evaluation of these
animals in adulthood (PN60) indicated no
signiﬁcant overall effect (Figure 7A), although
AC values tended to be decreased by the same
magnitude (10%) as that obtained for the
immediate posttreatment effects.
As reported previously (Auman et al. 2000),
CPF treatment on PN1–4 produced transient
elevations in hepatic AC responses to glucagon
and Mn2+ that disappeared by PN10. In the
present study, we also assessed short-term
effects on hepatic βAR binding, none of which
was statistically significant: PN5—control
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Figure 6. Effects of GD17–20 CPF exposure on
(A) cardiac and (B) hepatic βAR binding and AC
activity on PN60. Abbreviations: Fsk, forskolin; Glu,
glucagon; Iso, isoproterenol; NS, not signiﬁcant; Rx,
treatment. Data represent means and SEs obtained
from eight animals in each treatment group for each
sex, shown as the percent change from correspond-
ing control values (Table 1). Across both tissues,
ANOVA indicates signiﬁcant sex- and tissue-depen-
dent effects on βAR binding (p < 0.05 for treatment ×
sex × tissue). For AC activities, the overall ANOVA
showed treatment effects that differed between the
two tissues, between sexes, and among the differ-
ent AC measures (p < 0.02 for treatment × tissue; p <
0.007 for treatment × measure; p < 0.006 for treat-
ment × sex × measure), necessitating separate
comparisons for heart and liver. ANOVAs across
both CPF doses are as follows: for (A), Rx × sex, p <
0.003; Rx × measure, p < 0.05; male: NS; female: Rx,
p < 0.005; for (B), Rx × measure, p < 0.08. ANOVAs
for each dose are shown within the ﬁgure.
*Individual groups differ signiﬁcantly from the control (cal-
culated only for variables showing signiﬁcant treatment ×
measure and treatment × sex interactions after separation
by dose; otherwise, only the main effects are shown.
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Figure 7. Effects of PN1–4 CPF exposure (1 mg/kg)
on (A) cardiac and (B) hepatic βAR binding and AC
activity on PN60, and (C) activity ratios for liver val-
ues. Abbreviations: Fsk, forskolin; Glu, glucagon;
Iso, isoproterenol; NS, not significant; Rx, treatment.
Data represent means and SEs obtained from six
animals for each sex, shown as the percent change
from corresponding control values (Table 1). Across
both tissues, ANOVA indicates no significant
effects on βAR binding. For AC activities, the overall
ANOVA showed treatment effects that differed
between the two tissues, between sexes, and
among the different AC measures (p < 0.04 for treat-
ment × sex × tissue; p < 0.04 for treatment × tissue
× measure), necessitating separate comparisons
for heart and liver. Lower-order ANOVAs are shown
within the ﬁgure.
*Individual groups differ signiﬁcantly from the control (cal-
culated only for variables showing signiﬁcant treatment ×
measure and treatment × sex interactions).
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C
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Femalemale, 16.9 ± 0.5 fmol/mg protein (n = 5); con-
trol female, 14.5 ± 0.6 (n = 4); CPF male, 15.8
± 1.1 (n = 4); CPF female, 14.7 ± 0.5 (5);
PN10—14.5 ± 0.8 (n = 6), 12.5 ± 0.6 (n = 4),
13.2 ± 0.7 (n = 7), and 12.3 ± 0.8 (n = 7),
respectively. When these animals reached
adulthood, we still did not detect alterations in
βAR binding, but there were major, sex-depen-
dent effects on AC activities (Figure 7B). Basal
AC activity was unaffected, but males showed
elevations of AC responses to stimulants with
the notable exception of Mn2+. In females, AC
responses to stimulants were not augmented
and tended instead to be reduced. Because of
the strong, differential effect on AC responses
to speciﬁc stimulants, we characterized the pat-
tern by calculation of response ratios (Figure
7C). CPF exposure on PN1–4 elicited speciﬁc
activation of the responses to stimulants oper-
ating through G-proteins (isoproterenol,
glucagon, NaF) and preferentially enhanced
the response to forskolin as opposed to Mn2+.
We also performed an additional experi-
ment to identify whether the delayed-onset
effects on hepatic AC signaling appeared ear-
lier (Figure 8). By PN30, the elevations of AC
stimulant responses had not yet appeared, and
in fact, activities were signiﬁcantly lower than
in controls, again with a preferential effect
toward males.
CPF exposure on PN11–14. As evaluated
earlier (Song et al. 1997), animals exposed to
5 mg/kg CPF on PN11–14 showed reduc-
tions in cardiac βAR binding and AC
responses to βAR stimulation on PN20. In
the liver, the short-term effects consisted of
transient elevations in AC responses to
glucagon and Mn2+ that disappeared by PN20
(Auman et al. 2000). We did not ﬁnd signiﬁ-
cant effects on hepatic βAR binding on PN15
or PN20: PN15—control male, 9.3 ± 0.5
fmol/mg protein (n = 6); control female, 9.0 ±
1.7 (n = 6); CPF male, 9.8 ± 0.6 (n = 6); CPF
female, 6.9 ± 0.8 (n = 6); PN20—4.4 ± 0.5
(n = 6), 4.5 ± 0.3 (n = 6), 4.2 ± 0.4 (n = 6),
and 4.0 ± 0.5 (n = 6), respectively.
In adulthood, we found the same magni-
tude and direction of effect on cardiac AC as
was seen previously for short-term (PN20)
evaluations (Song et al. 1997), although with-
out achieving statistical signiﬁcance in the pre-
sent study (Figure 9A). A similar pattern was
seen in the liver (Figure 9B), and ANOVA
combined across the two tissues indicated a
significant overall AC reduction (p < 0.05)
despite a lack of signiﬁcance for either tissue
considered separately.
Discussion
Results of this study indicate that developmen-
tal CPF exposure elicits immediate and late-
emerging alterations in AC-mediated cell
signaling in the heart and liver, extending the
adverse effects of CPF beyond neurotoxicity.
Although CPF at high concentrations can
interact directly with neurotransmitter recep-
tors and/or AC (Huff and Abou-Donia 1995;
Huff et al. 1994, 2001; Ward and Mundy
1996), our results indicate that such direct
actions are unlikely to explain the net effects
on the development of AC signaling after in
vivo exposure: we found distinct sex-, tissue-,
and age-selective actions that are incompatible
with a unitary, stoichiometric interaction
between CPF and the signaling proteins.
Indeed, the fact that many of the effects
emerged after a prolonged delay (i.e., between
PN30 and PN60) indicates instead that CPF
exposure alters the programming of the devel-
opment of cell signaling. In light of the dis-
parate effects of the different CPF treatment
windows, it is worthwhile to examine the char-
acteristics that are shared by, or that differenti-
ate among, the various treatment paradigms
before arriving at general conclusions.
Although the major effects of CPF
emerged in adulthood, some acute effects were
detected in the period immediately after expo-
sure. With treatment on GD9–12, there was a
shift in the cardiac AC isoform, evidenced by a
preferential increase in the response to Mn2+ as
opposed to forskolin (Zeiders et al. 1999b).
For the GD17–20 treatment window, adverse
effects on hepatic signaling proﬁles emerged at
CPF doses above the threshold for systemic
toxicity. Similarly, our earlier work detailed
short-term effects of postnatal CPF treatments
on AC (Auman et al. 2000; Song et al. 1997).
However, none of these effects was sustained,
nor are they likely to explain the long-term
changes identified later. For example, there
were no immediate effects for the GD17–20
regimen at the subtoxic doses that nevertheless
produced robust effects on signaling in adult-
hood; similar discrepancies between acute and
long-term effects have already been noted in
the presentation of each set of results. In one
case similar outcomes were obtained over both
the immediate and the long-term time frames,
namely, the cardiac effects of CPF exposure on
PN11–14, but even in this situation the mag-
nitude of impairment was small and nonsignif-
icant. In general, then, the acute effects of CPF
on AC signaling were poorly correlated with
the subsequent emergence of major, sex-depen-
dent, tissue-selective functional alterations,
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Figure 8. Effects of PN1–4 CPF exposure (1 mg/kg)
on hepatic βAR binding and AC activity on PN30.
Abbreviations: Fsk, forskolin; Glu, glucagon; Iso,
isoproterenol; NS, not significant; Rx, treatment.
Data represent means and SEs obtained from six
animals for each sex, shown as the percent
change from corresponding control values for
males and females, respectively: βAR binding, 5.7 ±
0.2 and 6.0 ± 0.3 fmol/mg protein; basal AC, 3.3 ± 0.1
and 2.8 ± 0.1 pmol/min/mg protein; isoproterenol-
stimulated AC, 5.1 ± 0.2 and 4.7 ± 0.2 pmol/min/mg
protein; glucagon-stimulated AC, 27 ± 1 and 25 ± 2
pmol/min/mg protein; NaF-stimulated AC, 33 ± 1
and 30 ± 1 pmol/min/mg protein; forskolin-stimu-
lated AC, 65 ± 1 and 53 ± 2 pmol/min/mg protein;
Mn2+-stimulated AC, 51 ± 2 and 41 ± 1 pmol/min/mg
protein. ANOVA indicates no significant CPF
effects on βAR binding. For AC activities, the over-
all ANOVA (shown within the figure) displayed
treatment effects that differed between the two
sexes but not among the different AC measures, so
lower-order tests were not done for the individual
measures. Main treatment effects for each sex are
also shown.
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Figure 9. Effects of PN11–14 CPF exposure
(5 mg/kg) on (A) cardiac and (B) hepatic βAR bind-
ing and AC activity on PN60. Abbreviations: Fsk,
forskolin; Glu, glucagon; Iso, isoproterenol; Rx,
treatment. Data represent means and SEs obtained
from six animals for each sex, shown as the per-
cent change from corresponding control values
(Table 1). Across both tissues, ANOVA indicates
effects on βAR binding that differed between tissues
and sexes (p < 0.1 for treatment × sex; p < 0.03 for
treatment × tissue), but the sex interaction was not
maintained when the values were separated into
the two tissues; accordingly, only the main effect is
shown (B). For AC activities, the overall ANOVA
showed only a main treatment effect (p < 0.05) with-
out signiﬁcant interactions of treatment with other
variables, so separate tests or subtests were not
done for the two tissues, although the values are
shown separately. 
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Femaleimplying that CPF affects the developmental
program for cell signaling.
The second common feature for all the
exposure models is the fact that many of the
emergent effects on signaling were heterolo-
gous; that is, they involved ubiquitous changes
in the function of signaling proteins themselves
rather than in the speciﬁc responses to receptor
stimulation. Thus, the effects on AC tended to
appear in “clusters,” with increases or decreases
shared by different receptor stimulants (isopro-
terenol, glucagon), by a G-protein activator
(NaF), or by AC stimulants that bypass recep-
tors (forskolin) or receptors and G-proteins
(Mn2+). These heterologous changes thus indi-
cate that CPF alters the ability of the entire sig-
naling cascade to respond to the multiple
neuronal and hormonal inputs that elicit cellu-
lar responses through AC. Nevertheless, super-
imposed on these heterologous effects, we did
detect instances where CPF exposure affected a
speciﬁc input to the transduction pathway. As
one example, the effects on cardiac AC signal-
ing after exposure to 1 mg/kg CPF on
GD17–20 included speciﬁc impairment of the
response to glucagon in adulthood, superim-
posed on heterologous activation of other AC
responses. We also found evidence for AC iso-
form shifts, such as the alteration in the prefer-
ence ratio for forskolin versus Mn2+ in the liver
after PN1–4 CPF exposure; because the vari-
ous AC isoforms have distinct catalytic proper-
ties and differential responses to second
messengers, these too may provide a basis for
more selective functional alterations despite a
common origin in heterologous AC effects.
An additional feature common to all the
exposure models is the general dissociation of
effects on βAR binding from the AC response
to the βAR stimulant isoproterenol. Thus, on
GD21, the two prenatal CPF exposure regi-
mens affected cardiac βARs but not the corre-
sponding AC response; in the liver, the
GD17–20 treatment group displayed no
change or an increase in βARs on GD21, but
a decrease in the isoproterenol AC response.
A similar lack of parallelism was seen for the
other treatment paradigms and for the
delayed-onset alterations determined in adult-
hood. These results are consistent with the
view that the signaling proteins downstream
from the receptors are the major determinants
of functional responses (Gao et al. 1998,
1999; Navarro et al. 1991), so evaluations of
receptor binding alone may be entirely mis-
leading for the interpretation of physiologic
consequences.
Despite the fact that all the CPF exposure
windows shared major features of their effects
on cell signaling, there were distinct differences
that depended on the period of exposure.
Focusing on the long-term effects of low-dose
CPF exposures, cardiac AC showed augmenta-
tion with the prenatal treatment windows,
with a different critical period for effects on
males (GD9–12) versus females (GD17–20).
Smaller, nonsigniﬁcant inhibitory effects were
seen with postnatal exposures; therefore, the
critical window of sensitivity for CPF-induced
perturbation of cardiac AC signaling must
begin to close soon after birth. The liver dis-
played a different pattern, with sensitivity ﬁrst
emerging late in gestation, characterized by
long-term inhibitory effects after GD17–20
exposure. With later treatment on PN1–4,
effects were stimulatory and restricted to males,
whereas again, a shift to even later treatment
(PN11–14) elicited only small, nonsigniﬁcant
decrements. As a general observation, then, the
effects of CPF on the programming of AC cell
signaling occur during a distinct developmen-
tal window of vulnerability that closes in the
second postnatal week.
An additional point of interest is the sex
dependence of the effects of CPF on cardiac
and hepatic cell signaling, which shifts radically
according to the developmental window in
which exposure occurs. In the present study,
males were preferentially affected by most
treatment paradigms, with the notable excep-
tion of the selective effects on females seen
with the GD17–20 exposure. Although we
have no information about the mechanisms
underlying sex-selective actions, it is notable
that similar shifts have been seen for effects on
behavior from these particular treatment win-
dows (Dam et al. 2000; Levin et al. 2001,
2002). The late gestational period is associated
with sexual differentiation of the brain (Rodier
1988), and it is tempting to attribute the
unique pattern seen with exposure on
GD17–20 to effects on sexual dimorphism of
neural pathways. CPF is only weakly estrogenic
(Andersen et al. 2002; Vinggaard et al. 2000),
but certainly, secondary endocrine effects are
feasible (Guven et al. 1999). However, the fact
that sex-selective effects were seen even earlier,
with GD9–12 exposure, makes it unlikely that
all the differences can be explained by a pri-
mary action on sexual differentiation of the
brain. Obviously, this is an issue of consider-
able importance for future investigation.
Finally, there are two elements of the
delayed-onset emergence of abnormalities in
AC signaling that need to be addressed. First,
the alterations in receptor binding and AC
biomarkers ranged up to about 20%; this is
approximately the magnitude of the changes
evoked by CPF in the developing brain
(Aldridge et al. 2004; Meyer et al. 2003; Song
et al. 1997), by other deﬁned neurotoxicants
such as nicotine (Slotkin et al. 1992), or by
the loss of function associated with aging
(Fraeyman et al. 2000; Kilts et al. 2002).
Relatively small changes have important func-
tional consequences because the AC pathway
ampliﬁes receptor signals by orders of magni-
tude: the activation of a single AC molecule
leads to the production of numerous cAMP
molecules and consequent activation of pro-
tein kinase A, which in turn elicits a plethora
of downstream phosphorylation events
(Freissmuth et al. 1989; Gilman 1989; Stiles
1989; Weiss et al. 1988). During develop-
ment, these types of changes produce massive
changes in cellular functions linked to cAMP
despite modest changes in elements of the sig-
naling cascade itself (Schuh et al. 2002; Song
et al. 1997). Second, the dose–response rela-
tionships seen here are often complex. For
example, although many of the acute effects of
CPF show a typical, monotonic relationship
to dose, we noted several instances where the
effects did not progress beyond those seen at
lower doses, and even cases where effects dis-
played hormesis, with larger alterations at low
doses (e.g., Figures 3A, 4A). Indeed, a number
of other studies indicate nonmonotonic effects
of CPF at the biochemical and behavioral lev-
els (Levin et al. 2001, 2002; Meyer et al.
2003; Qiao et al. 2002, 2003), and we
recently found that this extends to AC signal-
ing in the brain (Aldridge et al. 2003, 2004).
One important distinction is whether a given
dose lies above the threshold for cholinesterase
inhibition, because, during fetal development,
cholinergic input can lead to lasting improve-
ments in neural performance (Meck and
Williams 1997, 1999; Montoya et al. 2000).
The doses used here bracket the threshold for
fetal cholinesterase inhibition (Qiao et al.
2002). Given the clear involvement of neural
input in the cardiac and hepatic effector
mechanisms studied here, similar factors may
then produce hormetic responses to AC in
these peripheral tissues.
The results obtained here indicate that
apparently subtoxic developmental exposures
to CPF, even at levels that do not produce sig-
niﬁcant inhibition of cholinesterase (Qiao et al.
2002), alter cardiac and hepatic cellular func-
tion in adulthood. There are four important
characteristics of these effects. First, the alter-
ations involve heterologous changes in signal-
ing components (G-proteins, AC itself) that
are shared by multiple neuronal and hormonal
stimulants. Accordingly, there will be global
effects on the responses to diverse inputs.
Second, these effects are sex selective, so future
work with animal models or human popula-
tions will need to take sex differences into
account. Third, the effects emerge late in
development, thus requiring longitudinal eval-
uations. Finally, superimposed on the heterolo-
gous changes in AC signaling, we found
speciﬁc alterations in the responses to glucagon
and βAR stimulation, both of which play criti-
cal roles in cardiovascular and metabolic
homeostasis, and with regard to the latter,
speciﬁcally glucose homeostasis. The secretion
of insulin, the counterbalancing hormone for
glucagon, proceeds through activation of AC
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tation of AC signaling caused by CPF exposure
is likely to amplify the physiologic effect of a
superimposed deficiency in the glucagon
response. It is now recognized that diseases that
occupy a distinct cluster—hypertension, obe-
sity, and diabetes—may have significant
dependence on prenatal stress and/or toxicant
exposures (Dodic et al. 1999, 2001; Nyirenda
and Seckl 1998; Power and Jefferis 2002;
Slikker and Schwetz 2003; Toschke et al.
2002). The present results point to the possi-
bility that otherwise subtoxic, nonsymptomatic
developmental exposure may provide predispo-
sition to these types of diseases, with a speciﬁc
component of delayed-onset effects. As such,
the adverse adult outcomes predicted by the
Barker Hypothesis may actually extend to
exposures below the threshold for fetal growth
impairment. Indeed, a number of the effects
on signaling cascades seen here for CPF expo-
sure have been examined in transgenic mice
overexpressing the corresponding receptors or
downstream transduction proteins, and clearly
indicate the emergence of cardiac myopathies
as well as hepatic dysfunction and damage
(Andre et al. 1999; Asai et al. 1999; Du et al.
2000; Singh et al. 2001; Vatner et al. 1999).
Nevertheless, given the multifactorial nature of
hypertension and diabetes, it seems unlikely
that the magnitude of the effects of develop-
mental CPF exposure on the AC cascade alone
would trigger these diseases, but instead might
provide a risk factor that acts in concert with
other comorbidities. Studies of CPF effects in
animal models of hypertension, obesity, and
diabetes are likely to resolve this issue, in con-
cert with examination of human cohorts with
signiﬁcant fetal or childhood CPF exposures.
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